GenMont Biotech Incorporation (TPE:3164)
15.45
-1.05 (-6.36%)
Nov 20, 2026, 1:30 PM CST
TPE:3164 Revenue
GenMont Biotech Incorporation had revenue of 103.43M TWD in the quarter ending September 30, 2026, with 16.34% growth. This brings the company's total for the last twelve months to 396.64M, up 1.32% year-over-year. In the year 2025, GenMont Biotech Incorporation had annual revenue of 401.23M with 4.11% growth. That makes GenMont Biotech Incorporation the 36,562nd largest company in the world by revenue and 1,911th in Taiwan.
Revenue (ttm)
396.64M
Revenue Growth
+1.32%
P/S Ratio
3.35
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.33B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full TPE:3164 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 401.23M | 15.86M | 4.11% |
| Dec 31, 2024 | 385.37M | 67.36M | 21.18% |
| Dec 31, 2023 | 318.02M | -50.53M | -13.71% |
| Dec 31, 2022 | 368.55M | -59.38M | -13.88% |
| Dec 31, 2021 | 427.93M | 102.74M | 31.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Synbio Tech | 1.03B |
| NeoCore Technology | 271.62M |
| G&E Herbal Biotechnology | 170.13M |
| Gwo Xi Stem Cell Applied Technology Co. , | 157.86M |
| TaiRx | 29.44M |
| Anti-Microbial Savior BioteQ | 1.26M |